# Suppressive Potential of Ethanolic Extracts of Parkia speciosa Hassk. Empty Pods Against Colon Cancer Cell Migration and Invasion

**Authors:** Athit Chaiwichien, Supawadee Osotprasit, Tepparit Samrit, Pornanan Kueakhai, Narin Changklungmoa

PMC · DOI: 10.3390/ijms27042072 · International Journal of Molecular Sciences · 2026-02-23

## TL;DR

This study shows that an extract from Parkia speciosa empty pods can inhibit colon cancer cell migration and invasion without harming normal cells.

## Contribution

The study is the first to investigate the anti-cancer properties of P. speciosa empty pods, revealing their potential as a natural treatment for colon cancer.

## Key findings

- PSET inhibited colorectal cancer cell migration, invasion, and colony formation in a dose-dependent manner.
- PSET reduced the expression of MMP2, MMP9, and N-cadherin, indicating suppression of EMT.
- The extract showed no cytotoxicity toward normal colon epithelial cells.

## Abstract

Parkia speciosa (P. speciosa), a plant utilized in traditional medicine, has shown promise in various therapeutic applications and contains multiple bioactive components (saponins, alkaloids, flavonoids, polyphenols, and terpenoids). These bioactive compounds have attracted increasing scientific interest due to their ability to modulate key cancer-associated pathways, including the inhibition of cell proliferation and migration and the suppression of oxidative stress and inflammation mechanisms. However, despite P. speciosa’s historically long and wide-ranging usage, a comprehensive investigation of these properties has not been conducted for its pod. This study investigated the effects of P. speciosa empty pod extract (PSET) on human colorectal cancer cells. The extract demonstrated significant dose-dependent inhibition of colorectal cell migration, invasion, and colony formation while exhibiting no cytotoxicity toward normal colon epithelial cells. Western blot analysis confirmed reduced expression of Matrix metalloproteinases 2 (MMP2), Matrix metalloproteinases 9 (MMP9), and N-cadherin, indicating suppression of the epithelial–mesenchymal transition (EMT). These findings demonstrate that the PSET effectively inhibits metastasis in colorectal cancer cells through the EMT pathway, suggesting its potential as a dietary supplement or therapeutic agent for colorectal cancer treatment. Our research provides support for the development of natural, less toxic alternative cancer treatments. Therefore, PSET shows potential for development as a dietary supplement or therapeutic agent for the treatment of colon cancer.

## Linked entities

- **Proteins:** CadN (Cadherin-N)
- **Diseases:** colon cancer (MONDO:0002032), colorectal cancer (MONDO:0005575)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, VIM (vimentin) [NCBI Gene 7431], CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}
- **Diseases:** colon (MESH:D003108), colon adenocarcinoma (MESH:D003110), PSET (MESH:D004652), injury to (MESH:D014947), inflammation (MESH:D007249), metastasis (MESH:D009362), Colon Cancer (MESH:D015179), cardiovascular disease (MESH:D002318), diabetes (MESH:D003920), cancer (MESH:D009369), metastatic (MESH:D000092182), Cytotoxicity (MESH:D064420)
- **Chemicals:** alpha-amyrin (MESH:C000654244), 5-Fluorouracil (MESH:D005472), polyphenols (MESH:D059808), CO2 (MESH:D002245), L-glutamine (MESH:D005973), penicillin G (MESH:D010400), hyperin (MESH:C021304), terpenoids (MESH:D013729), theasinensin A (MESH:C481298), Tween 20 (MESH:D011136), epigallocatechin (MESH:C057580), SDS (MESH:D012967), alkaloids (MESH:D000470), ethanol (MESH:D000431), D-glucose (MESH:D005947), DMSO (MESH:D004121), flavonoid (MESH:D005419), saponins (MESH:D012503), ROS (MESH:D017382), McCoy's 5A medium (MESH:C113109), sodium bicarbonate (MESH:D017693), PBS (-), epigallocatechin gallate (MESH:C045651), crystal violet (MESH:D005840), palmitoleic acid (MESH:C008757), methanol (MESH:D000432), 1,2,3-benzenetriol (MESH:D011748), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MESH:C022616), unsaturated fatty acids (MESH:D005231), doxorubicin (MESH:D004317), hexadecenoic acid (MESH:C093821), gallic acid (MESH:D005707), oxaloacetic acid (MESH:D062907), urea (MESH:D014508), Quercetin (MESH:D011794), MTT (MESH:C070243), vitamin E (MESH:D014810), myricitrin (MESH:C008577), triterpenes (MESH:D014315), piperine (MESH:C008922), streptomycin (MESH:D013307), phytosterols (MESH:D010840), polyacrylamide (MESH:C016679), Rutin (MESH:D012431)
- **Species:** Polyspora speciosa (species) [taxon 182316], Parkia speciosa (species) [taxon 148714], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HCT-116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), CCD-18Co — Homo sapiens (Human), Finite cell line (CVCL_2379), SW480 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0546), CRL-1459TM — Homo sapiens (Human), Hyperlipoproteinemia, type IIa, Transformed cell line (CVCL_4N15), SW620 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0547), H-T29 — Homo sapiens (Human), Transformed cell line (CVCL_2G69)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940531/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940531/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940531/full.md

---
Source: https://tomesphere.com/paper/PMC12940531